Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 358-363

  Connick, Elizabeth ^a,i   Lederman, Michael M ^b   Kotzin, Brian L ^a   Spritzler, John ^c   Kuritzkes, Daniel R ^a   St Clair, Marty ^d   Sevin, Anne D ^c   Fox, Lawrence ^e   Chiozzi, Margo Heath ^f   Leonard, John M ^f   Rousseau, Franck ^d,h   D'Arc Roe, Joana ^e   Martinez, Ana ^e   Kessler, Harold ^g   Landay, Alan ^g  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d GLAXOSMITHKLINE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f ABBOTT LABORATORIES   (United States)

^g RUSH MEDICAL COLLEGE   (United States)

^h Hamner Institutes for Health Sciences   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RITONAVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-HIV AGENTS; CANDIDA; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNE SYSTEM; LAMIVUDINE; MUMPS VIRUS; RITONAVIR; RNA, VIRAL; ZIDOVUDINE;

EID: 0033984368     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315171     Document Type: Article

References (14)

1. + T cell subset phenotyping independently predict survival time in patients infected with the human immunodeficiency virus. J Infect Dis 1995; 172:79-87.
2. 2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
3. + T cell homeostasis and function in advanced HIV disease, Science 1997; 277:112-6.
4. 4. Plana M, Garcis F, Gallart T, Miro JM, Gatell JM. Lack of T-cell proliferation response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Lancet 1998; 352:1194-5.
5. 5. Pakker NG, Roos M, Leeuwen R, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immun Defic Syndr Hum Retrovirol 1997; 16:318-26.
6. 6. Li TS, Tubiana R, Katlama C, Calvez V, Mohand HA, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-6.
7. 7. Rinaldo RR Jr, Liebmann JM, Huang XL, et al. Prolonged suppression of human immunodeficiency virus type I (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999; 179:329-36.
8. 8. Pontesilli O, Kerkhof-Garde S, Notermans DW, et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999; 180:76-86.
9. 9. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS clinical trials group protocol 315. J Infect Dis 1998; 178:70-9.
10. 10. Thompson NJ, Glasroth J, Sinder D, Farer L. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979; 119:587-97.
11. 11. Pakker NG, Notermans DW, De Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Med 1998; 4: 208-14.
12. + cell counts despite persistently detectable HIV load. N Engl J Med 1998; 338:1074-5.
13. 13. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351:723-4.
14. 14. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med 1999; 340:1301-6.